Granted Patent B2

US 11,129,873 · App. 16/054,107 · Granted Sep 28, 2021

Inventors: John Knopf (Carlisle, MA); Jasbir Seehra (Lexington, MA)

Assignee: ACCELERON PHARMA INC.

A61K38/179C07K14/575C07K14/71A61K38/00C07K2319/30C07K2319/32C07K2319/35C07K2319/70

Abstract

Claims (12)

1. A method of identifying an agent that inhibits bone resorption, the method comprising: a) identifying an agent that binds to a ligand-binding domain of an ActRIIa polypeptide competitively with an activin or ActRIIa antagonist polypeptide; and b) evaluating the effect of the agent on bone tissue.

2. The method of claim 1 , wherein the agent is selected from the group consisting of non-peptidyl organic molecules, peptides, polypeptides, peptidomimetics, sugars, hormones, and nucleic acid molecules.

3. The method of claim 1 , wherein the agent is identified by a biochemical method.

4. The method of claim 1 , wherein the agent is identified by a mechanism based assay.

5. The method of claim 1 , wherein the agent is evaluated in a cell-based assay.

6. The method of claim 1 , wherein the agent is evaluated in an in vivo assay.

7. The method of claim 1 , wherein the ActRIIa polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

8. The method of claim 1 , wherein the ActRIIa polypeptide comprises the amino acid sequence of SEQ ID NO: 3.

9. The method of claim 1 , wherein the ActRIIa polypeptide comprises the amino acid sequence of SEQ ID NO: 7.

10. The method of claim 1 , wherein the ActRIIa polypeptide comprises the amino acid sequence of SEQ ID NO: 12.

11. The method of claim 1 , wherein the N-terminus of the ActRIIa polypeptide is ILGRSETQE (SEQ ID NO: 11).

12. The method of claim 1 , wherein the ActRIIa polypeptide consists of the amino acid sequence of SEQ ID NO: 7.

Assignments (1)

Continuity (9)